HCA

HCA Healthcare
D

HCA

Arincen59/100B

HCA Healthcare P/E ratio

HCA Healthcare's P/E ratio is 16.35: its share price of 495.02 over its earnings per share of 30.27 over the last twelve months.

Today
16.35
Forward P/E, next 12 months
15.89
PEG ratio
1.73
Median, 5 years
14.24
Low, 5 years
7.65
High, 5 years
19.71

P/E ratio = price ÷ EPS (last 12 months) = 495.02 ÷ 30.27 = 16.35

Each day's closing price over the earnings per share of the last four quarters reported by that day (basic EPS, adjusted for splits). The P/E moves with the price every day and with the earnings at each report.

The forward P/E divides the price by the analysts' average EPS estimate for the next twelve months: the fiscal year in progress for the months left in it, the next one for the rest. For past days it uses each year's latest estimate, as the estimates of the time were not recorded (we keep a daily copy from November 2026), so the past line reads the price against the earnings expected by the time each year was reported.

Is HCA Healthcare's P/E high compared with its own history?

HCA Healthcare's P/E of 16.4 is above the middle of its 5-year range (7.6 to 19.7, median 14.2). Analysts do not expect faster growth than in recent years, so it is expensive compared with its own history.

Is the price fair? See the whole check

A P/E is compared with the stock's own last five years, not with other companies. Why the market pays more or less (news, rates, the sector) is not in these figures.

P/E ratio by year and by quarter

Fiscal yearPeriod endingP/E ratioForward P/EMarket capNet income
FY2027 · Estimate31 Dec 202715.80———
FY2026 · Estimate31 Dec 202616.44———
Today16.3515.89103.41B6.78B
FY202531 Dec 202515.8815.51107.71B6.78B
FY202431 Dec 202411.6610.8577.62B6.66B
FY202331 Dec 202314.0712.3673.73B5.24B
FY202231 Dec 202210.1913.1869.67B6.83B
FY202131 Dec 202110.769.2283.07B7.72B
FY202031 Dec 202012.729.2255.82B4.39B
FY201931 Dec 201912.1713.3550.43B4.15B
FY201831 Dec 20189.7211.8442.67B4.39B
FY201731 Dec 201711.2111.2830.75B2.74B
FY201631 Dec 20167.9911.2827.43B3.43B
FY201531 Dec 201510.0010.0626.97B2.70B
FY201431 Dec 201413.0013.9130.86B2.37B
FY201331 Dec 201310.5113.8520.97B2.00B
FY201231 Dec 20126.679.5813.37B2.01B
FY201131 Dec 20113.696.8310.50B2.84B
FY201031 Dec 20108.41—13.23B1.57B
FY200931 Dec 20097.71—10.61B1.38B
FY200831 Dec 200815.76—10.61B673.00M
FY200731 Dec 200712.14—10.61B874.00M
FY200631 Dec 200612.08—12.51B1.04B
FY200531 Dec 20059.59—13.65B1.42B
FY200431 Dec 200411.84—14.75B1.25B
FY200331 Dec 200311.66—15.53B1.33B
FY200231 Dec 200219.03—15.85B833.00M
FY200131 Dec 200118.36—16.26B886.00M
FY200031 Dec 200077.55—16.98B219.00M
FY199931 Dec 199931.20—20.50B657.00M
FY199831 Dec 199837.62—20.01B532.00M
FY199731 Dec 1997163.23—20.57B126.00M
FY199631 Dec 199613.85—20.84B1.51B
FY199531 Dec 199521.54—20.70B961.00M
FY199431 Dec 199419.62—16.03B817.00M
FY199331 Dec 199325.34—14.98B591.00M
FY199231 Dec 199239.16—1.01B25.90M
FY199131 Dec 199150.85—772.96M15.20M
FY199031 Dec 199056.40—552.72M9.80M

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters. A forecast year's P/E is today's price over the analysts' EPS estimate for that year.

See also:Market cap,P/S ratio,Dividend yield,Current ratio,All ratios

Common questions about HCA Healthcare's P/E ratio

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.